一分钟看懂
这是一项关于黑色素瘤的II 期研究，登记的药物或干预包括Biopsy Procedure；Biospecimen Collection；Cabozantinib S-malate；Computed Tomography；Magnetic Resonance Imaging；Nivolumab，当前状态为招募中。登记地点显示中国Phoenix、Little Rock、Beverly Hills、Irvine等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Biopsy Procedure；Biospecimen Collection；Cabozantinib S-malate；Computed Tomography；Magnetic Resonance Imaging；Nivolumab · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Mayo Clinic Hospital in Arizona · Phoenix
- University of Arkansas for Medical Sciences · Little Rock
- Tower Cancer Research Foundation · Beverly Hills
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care · Irvine
- The Angeles Clinic and Research Institute - West Los Angeles Office · Los Angeles
- Los Angeles General Medical Center · Los Angeles
- USC / Norris Comprehensive Cancer Center · Los Angeles
- Cedars-Sinai Medical Center · Los Angeles
- UC Irvine Health/Chao Family Comprehensive Cancer Center · Orange
- Rocky Mountain Regional VA Medical Center · Aurora
- UCHealth Memorial Hospital Central · Colorado Springs
- Memorial Hospital North · Colorado Springs
- Poudre Valley Hospital · Fort Collins
- Cancer Care and Hematology-Fort Collins · Fort Collins
- UCHealth Greeley Hospital · Greeley
- Medical Center of the Rockies · Loveland
- Helen F Graham Cancer Center · Newark
- Medical Oncology Hematology Consultants PA · Newark
- Mayo Clinic in Florida · Jacksonville
- Hawaii Cancer Care Inc - Waterfront Plaza · Honolulu
- Queen's Cancer Cenrer - POB I · Honolulu
- Queen's Medical Center · Honolulu
- Queen's Cancer Center - Kuakini · Honolulu
- Hawaii Cancer Care - Westridge · ‘Aiea
- Saint Alphonsus Cancer Care Center-Boise · Boise
- Saint Luke's Cancer Institute - Boise · Boise
- Saint Alphonsus Cancer Care Center-Caldwell · Caldwell
- Kootenai Health - Coeur d'Alene · Coeur d'Alene
- Saint Luke's Cancer Institute - Fruitland · Fruitland
- Saint Luke's Cancer Institute - Meridian · Meridian
公开的入选条件
- SPECIMEN SUBMISSION
- * Participants must have histologically confirmed melanoma that is stage III or IV, unresectable, recurrent, or metastatic non-uveal melanoma OR Participants must have histologically confirmed squamous cell carcinoma of the head and neck (HNSCC) that is either
- Note: For participants with primary oropharyngeal cancer, human papillomavirus (HPV) or p16 status must be known prior to step 1 registration
- * Participants must have disease presentation consistent with measurable disease. Note: Current disease measurements will not be required until step 2 registration
- * Participants must have had documented progression during or within 12 weeks after the last dose of PD-1 checkpoint inhibition-based therapy. Participants must have been receiving checkpoint inhibition for a minimum of 6 weeks. Participants who recur during a
- * Participants with known human immunodeficiency virus (HIV)-infection must be receiving anti-retroviral therapy and have an undetectable viral load test within 6 months prior to step 1 registration
- * Participants with evidence of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load within 28 days prior to step 1 registration
- * Participants with a history of hepatitis C virus (HCV) infection must have no detectable viral load within 28 days prior to step 1 registration
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05136196；登记信息更新于 2026-09-17。